ScreenerHero
TRLVTrulieve Cannabis Corp. Subordinate Voting Shares
AMEX · US · Healthcare · Drug Manufacturers - Specialty & Generic · trulieve.com
10.45USD+3.62%Mkt Cap: 1.94B $P/E: —

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through hom…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.94B $
Enterprise Value2.07B $
Revenue (TTM)1.14B $
Gross Profit711.17M $
Net Income (TTM)-116.38M $
Revenue/Share5.931 USD
Last Price10.45 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)23.07
PEG—
EV/EBITDA6.89
EV/Revenue1.82
P/S1.64
P/B1.60
EPS (TTM)-2.44
EPS (Forward)0.42
52W Range
4.61667% of range13.28
52W High13.28 USD
52W Low4.616 USD
Profitability
Gross Margin60.21%
Oper. Margin12.84%
EBITDA Margin26.43%
Profit Margin-9.85%
ROE-10.02%
ROA-4.32%
Growth
Revenue Growth-10.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF272.82M $
CapEx (TTM)60.51M $
FCF Margin20.37%
FCF Yield11.95%
Net Debt252.45M $
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity0.49
Current Ratio5.94
Quick Ratio3.71
Book Value/Sh6.072 USD
Cash/Share1.690 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.18 USD
Upside (mean)+73.9%
Target Range15.00 USD – 21.00 USD
$15.00+73.9% to mean$21.00
# Analysts7
Ownership
Shares Out.169.98M
Float167.89M
Insiders1.34%
Institutions20.80%
Short Interest
Short Ratio1.4d
Short % Float0.80%
Short % Out.0.69%
Shares Short1.32M
Short (prev mo.)809.95K
Technical
SMA 509.274 (+12.7%)
SMA 2007.767 (+34.6%)
Beta1.72
S&P 52W Chg20.80%
Avg Vol (30d)838.12K
Avg Vol (10d)819.91K
Technical Indicators
RSI (14)63.2
MACD0.2105
MACD Signal0.0541
MACD Hist.+0.1564
BB Upper9.936 USD
BB Middle8.875 USD
BB Lower7.814 USD
BB Width23.91%
ATR (14)0.5829 USD
Vol Ratio (20d)1.80x